Bruno Brochet Selected Research

Multiple Sclerosis

4/2024	ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
12/2023	Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
1/2022	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
1/2022	Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
12/2021	Cognitive Rehabilitation in Multiple Sclerosis in the Period from 2013 and 2021: A Narrative Review.
1/2021	Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data.
12/2020	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
8/2020	Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis.
1/2020	Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
1/2020	Evaluation of emotional disorders before and during treatment with interferon beta in patients with multiple sclerosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruno Brochet Research Topics

Disease

21	Multiple Sclerosis 04/2024 - 01/2002
3	Relapsing-Remitting Multiple Sclerosis 01/2019 - 02/2016
2	Disease Progression 01/2021 - 12/2020
2	Chronic Progressive Multiple Sclerosis 12/2020 - 01/2017
2	Infections 12/2020 - 01/2020
2	Myelitis 01/2020 - 01/2012
2	Progressive Multifocal Leukoencephalopathy 12/2016 - 09/2013
2	Cognitive Dysfunction 04/2016 - 12/2015
2	Brain Neoplasms (Brain Tumor) 12/2015 - 10/2004
2	Edema (Dropsy) 10/2011 - 08/2011
2	Demyelinating Diseases (Demyelinating Disease) 09/2008 - 01/2002
1	Prostatic Neoplasms (Prostate Cancer) 01/2021
1	COVID-19 01/2020
1	Transverse Myelitis (Necrotizing Myelitis) 01/2020
1	Dementia (Dementias) 01/2018
1	Fatigue 11/2017
1	Optic Neuritis (Retrobulbar Neuritis) 10/2017
1	Neuromyelitis Optica (Devic's Disease) 09/2017
1	Alzheimer Disease (Alzheimer's Disease) 04/2016
1	Glioma (Gliomas) 12/2015
1	Leukoencephalopathies 01/2012
1	Cicatrix (Scar) 10/2011
1	Encephalitis (Encephalitis, Rasmussen) 10/2011
1	Inflammation (Inflammations) 10/2011
1	Gliosis 10/2011
1	Hydrocephalus (Hydrocephaly) 08/2009
1	Neoplasms (Cancer) 10/2004
1	Brain Infarction 10/2004
1	Stroke (Strokes) 10/2004
1	Atherosclerotic Plaque (Atheroma) 10/2004
1	Abnormal Reflex (Hyperreflexia) 01/2004
1	Chronic Pain 06/2003
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2002

Drug/Important Bio-Agent (IBA)

5	Natalizumab (Tysabri)FDA Link 11/2017 - 09/2013
3	ocrelizumabIBA 04/2024 - 01/2020
3	AntibodiesIBA 01/2020 - 01/2002
3	Biomarkers (Surrogate Marker)IBA 12/2015 - 10/2004
2	Cladribine FDA LinkGeneric 12/2023 - 01/2022
2	TabletsIBA 12/2023 - 01/2022
2	teriflunomideIBA 01/2022 - 01/2019
2	Dimethyl FumarateIBA 01/2022 - 01/2019
2	Immunoglobulin G (IgG)IBA 09/2017 - 08/2011
2	Fingolimod Hydrochloride (FTY720)FDA Link 02/2016 - 04/2014
2	Contrast MediaIBA 07/2012 - 10/2004
2	GadoliniumIBA 07/2012 - 08/2011
2	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA 07/2012 - 10/2004
2	Aquaporin 4IBA 10/2011 - 08/2009
1	Immunologic Factors (Immunomodulators)IBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 08/2020
1	Myelin-Oligodendrocyte GlycoproteinIBA 01/2020
1	Oxygen (Dioxygen)IBA 01/2020
1	Interferon-betaIBA 01/2020
1	Rituximab (Mabthera)FDA Link 01/2019
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 09/2017
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2017
1	Methylprednisolone FDA LinkGeneric 01/2017
1	Biotin (Vitamin H)FDA Link 11/2016
1	Memantine (Namenda)FDA Link 04/2016
1	N-Methylaspartate (NMDA)IBA 04/2016
1	Glutamate Receptors (Glutamate Receptor)IBA 04/2016
1	Temozolomide (Temodar)FDA LinkGeneric 12/2015
1	SteroidsIBA 08/2012
1	ferric oxide (iron oxide)IBA 07/2012
1	Oligoclonal BandsIBA 01/2012
1	InterleukinsIBA 10/2011
1	Aquaporins (Water Channels)IBA 10/2011
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 10/2011
1	CytokinesIBA 08/2011
1	CuprizoneIBA 09/2008
1	Capsaicin (Zostrix)FDA Link 01/2004
1	resiniferatoxinIBA 01/2004
1	Analgesics (Analgesic Drugs)IBA 06/2003
1	S-nitrosocysteineIBA 01/2002
1	Cysteine (L-Cysteine)FDA Link 01/2002
1	Myelin Basic ProteinIBA 01/2002
1	Peptides (Polypeptides)IBA 01/2002

Therapy/Procedure

8	Therapeutics 01/2021 - 09/2017
1	Injections 01/2022
1	Cognitive Training 12/2021
1	Castration 01/2021
1	Plasma Exchange 08/2020
1	Tertiary Prevention 01/2018
1	Radiotherapy 12/2015
1	Drug Therapy (Chemotherapy) 12/2015